Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Oncologics Drove FDA’s 2012 Novel Approval Count To 15-Year High

Jan 07 2013

• By Bridget Silverman

Related Content

What's "New" at FDA?

Nov 16 2012

Evolution, Not Revolution, Marks Progress In Targeted Oncology Therapy – AACR

Oct 01 2012

Innovation Pays: Priority Drugs Drove Novel 2011 Approvals To New Heights

Jan 01 2012

FDA Wants To Help You Develop Drugs

Dec 06 2012

Oncology Review Division At The Head Of The Pack – But Can The Others Keep Up?

Apr 01 2012

Will The New Math Of Oncology Drug Review Times Carry Over Into PDUFA V?

Nov 01 2012

Related Companies

Vertex Pharmaceuticals Incorporated

Bristol Myers Squibb Company

Pfizer Inc.

Genentech, Inc.

Curis, Inc.

Medivation, Inc.

Salix Pharmaceuticals Ltd.

Genentech, Inc.

ARIAD Pharmaceuticals, Inc.

Teva Pharmaceutical Industries Ltd.

Windtree Therapeutics, Inc.

Wyeth

Protalix BioTherapeutics, Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Roche Holding AG

Curis, Inc.

Novartis AG

GSK plc

Human Genome Sciences, Inc.

Johnson & Johnson

Johnson & Johnson

Forest Laboratories, Inc.

Astellas Pharma, Inc.

Eisai Co., Ltd.

Arena Pharmaceuticals, Inc.

Ivax Corp.

Teva Pharmaceutical Industries Ltd.

Affymax, Inc.

Additional Topics

Approvals BioPharmaceutical

More from Approvals

More from Product Reviews

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window